Xilio Therapeutics (XLO) Current Leases (2020 - 2026)

Xilio Therapeutics has disclosed Current Leases across 7 years of filings, most recently posting $1.4 million for Q2 2026.

• In Q2 2026, Current Leases rose 12.82% year-over-year to $1.4 million; the TTM figure through Jun 2026 stood at $1.4 million (up 12.82% YoY), while the FY2025 annual figure was $1.3 million, up 13.05% from the prior year.
• Current Leases came in at $1.4 million for Q2 2026 at Xilio Therapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.4 million in Q2 2026 to a low of $829000.0 in Q1 2022.
• Average Current Leases over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
• Year-over-year, Current Leases grew 14.88% in 2022 and increased 12.82% in 2026.
• Over 5 years, Current Leases stood at $918000.0 in 2022, then grew by 14.05% to $1.0 million in 2023, then increased by 13.47% to $1.2 million in 2024, then advanced by 13.05% to $1.3 million in 2025, then climbed by 6.18% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.4 million in Q2 2026, $1.4 million in Q1 2026, and $1.3 million in Q4 2025.